BioSpace News Archive

Drug Development

Gilead’s Trodelvy Data Leaves Some Questioning Clinical Advantage

Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology’s annual meeting.

June 6, 2022
·
3 min read
·
Vanessa Doctor, RN
BioMidwest

Lilly & Boehringer’s Diabetes Drug Slashes Hospitalization Risk for HF by 50%

The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.

June 6, 2022
·
3 min read
·
Mark Terry
Drug Development

New NSCLC Data Supports Combination of BMS’ Opdivo and Yervoy

The combination of Opdivo plus Yervoy in addition to chemotherapy demonstrated additional benefits in patient populations who usually have poor prognoses.

June 6, 2022
·
3 min read
·
Hannah Chudleigh
Drug Development

Positive Data Bolster ImmunityBio’s BLA in Bladder Cancer

Data presented in bladder and pancreatic cancer at ASCO underscore the company’s vision of using NK cells and T cells to target difficult-to-treat cancers.

June 6, 2022
·
2 min read
·
Alex Keown
Drug Development

Jobs on the Chopping Block as Praxis Gutted by MDD Failure

The Phase II/III Aria Study was unsuccessful in achieving statistical significance on the primary endpoint or any secondary objectives, according to Praxis.

June 6, 2022
·
2 min read
·
Paul Besabella
Drug Development

Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided additional data on patients dosed in Part A of its Phase 1/2 clinical trial of VX‑880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with T1D with impaired hypoglycemic awareness and severe hypoglycemia.

June 6, 2022
·
10 min read
Genetown

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of data from the EMERALD phase 3 clinical trial (NCT03778931).

June 6, 2022
·
8 min read
BioForest

Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.

June 6, 2022
·
18 min read
BioForest

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.

June 6, 2022
·
18 min read
Business

Ultima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated Computing

Ultima Genomics, Inc. today unveiled a broad collaboration with NVIDIA that leverages AI-accelerated analysis across multiple stages of the DNA sequencing and analysis process.

June 6, 2022
·
3 min read